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Abstract 
The loss of mitochondrial function has been implicated in a number of maladies such as 
Huntington’s Disease, Parkinson’s Disease, cancer and cardiovascular disease. The objective of 
this research was to develop a radiolabeled mitochondrial probe. Two tracers, 7´-Z-iodorotenol 
and 7´-Z-iodorotenone, analogs of rotenone a natural product that inhibits Complex I of the 
mitochondrial electron transport chain, have been labeled with iodine-125 in 45-85% yield in a 
single step from the corresponding tribuytylstannyl precursor. In vivo distribution in adult male 
Sprague-Dawley rats for both compounds showed high accumulation in the heart (1.7-3.7 %ID/g 
at 1h), a tissue with high mitochondrial content. Z-Iodorotenol did not washout of most tissues 
between 1 and 2 h post injection whereas Z-iodorotenone showed moderate washout (7-26%) 
over the same period. By 24 h there was significant loss of both compounds from most tissues 
including the heart. Heart-to-blood, -lung and -liver ratios for Z-iodorotenone of 28.9, 10.7 and 
2.4, respectively, were two- to four-fold higher than the Z-iodorotenol ratios. Compared to the 
current clinical perfusion tracers, 99mTc-sestamibi and 99mTc-tetrofosmin, Z-iodorotenone 
demonstrates similar 1h heart accumulation and significantly higher heart-to-lung ratio (P 
<0.001). Z-Iodorotenone heart-to-liver ratio is equivalent to 99mTc-sestamibi. 7´-Z-Iodorotenone 
possesses distribution characteristics of an improved tracer for SPECT perfusion studies.
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1. Introduction 
Mitochondrial dysfunction has been linked to normal aging processes as well as a variety of 
diseases including neurodegeneration (Alzheimer’s, Huntingon’s and Parkinson’s diseases) [1], 
cancer, osteoarthritis and cardiovascular disease. Wallace and colleagues have gathered evidence 
supporting a unified threshold hypothesis [2]. Wallace posits that each individual is born with a 
given mitochondrial mass. As one ages mutations to the mitochondrial DNA (mtDNA) 
diminishes the mitochondrial energy capacity.  Organ failure or disease may ensue if the 
mitochondrial capacity falls below a certain threshold in a given organ system. Normal aging is 
defined under this hypothesis as a slow loss of energy capacity over ones lifetime ultimately 
leading to progressive system failure. Mitochondrial-related disease is characterized by either an 
inherited genetic defect that significantly lowers the initial amount of mitochondria or 
environmental factors such as oxidative damage to mtDNA that speeds up the energy capacity 
loss as postulated in the case of Parkinson’s Disease [3, 4]. 
 Rotenone (1, Figure 1), a natural product found in the roots of the tropical Derris plant, has 
been shown to be a potent reversible inhibitor (IC50 = 0.25 nM) of Complex I of the 
mitochondrial electron transport chain [5]. Rotenone and preparation of crude root extracts have 
been widely used as “organic” insecticides and piscicides, due to their biological activity and 
rapid breakdown to environmentally benign byproducts [6, 7].  Several rotenonids have been 
isotopically labeled with 13C, 14C, 2H and 3H for structural studies [8] and to assess Complex I 
activity in vivo and in particular the loss of Complex I related to Parkinson’s Disease (PD) [9]. 
Tritiated (6',7')-dihydrorotenone [10] has been used to determine the regional distribution of 
Complex I in rodent brain [11, 12] as well as to assess binding to intact human platelets as a 
potential biomarker of PD [13].  
 Positron labeled analogs have been developed and evaluated as prospective in vivo imaging 
probes of Complex I activity. The brain distribution of two carbon-11 labeled radiotracers, (2-
[11C]methoxy)rotenone and (2-[11C]methoxy)-6´,7´-dihydroroten-12-ol, were evaluated in balb/c 
female mice [14, 15]. The regional distribution in the mouse brain was relatively equivalent with 
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the overall brain uptake of the rotenol being higher than that of the rotenone. Further assessment 
of the [11C]dihydrorotenol in unilateral intrastriatal quinolinic acid and MPP+ lesioned rats 
demonstrated the in vivo sensitivity of the tracer to the loss of Complex I in the striatum [16, 17]. 
Fluorine-18 labeled rotenone analogs, 6',7'-dihydro-7'-fluororotenone and 12-deoxy-6',7'-
dihydro-7'-fluororotenone, have been produced and evaluated in rats. Both compounds exhibited 
rapid clearance from the blood accompanied by early uptake in the brain and heart [18-20]. The 
12-deoxy compound cleared from brain and heart indicative of its reduced Complex I affinity. 
While several of these tracers possess suitable imaging characteristics, the Complex I imaging 
capabilities of these tracers has yet to be fully exploited. 
 Ongoing studies in our laboratory have corroborated the heart uptake seen in the Emory 
studies [18] and have demonstrated the avidity of the labeled rotenone analogs for the heart. 
Initial assessment of the 7' (Z)-[125I]iodorotenone and 6',7'-dihydro-7´-[18F]fluororotenone in the 
isovolumic, retrograde, red blood cell-perfused rabbit heart demonstrated the high extraction and 
retention of the rotenones as a function of blood flow [21, 22]. Both analogs possessed better 
linearity with flow than the current clinical tracer 99mTc-sestamibi, a tracer that accumulates in 
the heart tissue based on the mitochondrial membrane potential.[23, 24] It is not surprising that 
the rotenone analogs accumulate in the heart tissue given that mitochondria represent 20-30% of 
the myocardial mass.[25] Thus, given their distribution and biologic properties labeled rotenones 
represent a new class of potential cardiac perfusion tracers. 
 The detailed syntheses of two radioiodinated rotenone analogs, 7'-(Z)-iodorotenol (4, Scheme 
1) and 7'-(Z)-iodorotenone (5, Scheme 1), are reported herein. The corresponding iodine-125 
labeled derivatives were prepared by iododestannylation of the tributylstannane intermediates. 
Additionally, the biological distribution of both radiotracers was evaluated in normal Sprague-
Dawley rats.  
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Figure 1. 5'(R), 6a(S), 12a(S)-Rotenone structure shown with the conventional numbering 
system [8]. 
 
2. Materials and methods 
2.1 General 
 All chemicals and solvents were obtained from Aldrich Chemical Co. (Milwaukee, WI) and 
were used without further purification. Solvents were dried by standard techniques. All reactions 
were performed under a nitrogen atmosphere. High-performance liquid chromatography (HPLC) 
was performed using a Waters 590 solvent pump with an in-line Linear™ Model UV-106 UV 
detector (254 nm). An in-line NaI(Tl) radioactivity detector was added for radioHPLC. Melting 
points were determined using a Mel-Temp apparatus and are reported uncorrected. The 1H NMR 
spectra were recorded with either a Bruker 300 or 400 MHz spectrometer with CDCl3 as the 
internal standard (δ 7.26 ppm). Elemental analyses were performed by the Microanalytical 
Laboratory, operated by the College of Chemistry, University of California, Berkeley. High 
resolution (HRMS) and low resolution (LRMS) mass spectral determinations (EI or FAB) were 
made at the Midwest Center for Mass Spectrometry, University of Nebraska-Lincoln. High 
specific activity (2175 Ci/mmol) Na[125I]iodide in pH 9-12 aqueous 0.1M NaOH was purchased 
from Perkin Elmer Life Sciences. 
 Rotenol (2) was prepared by previously reported methods.[26] 
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2.2  6'-Oxo-7'-desmethylene-rotenol (3) 
 To a solution of 2 (4.7 g, 11.9 mmol) in THF (100 mL) and water (40 mL) was added a small 
crystal of OsO4. After stirring for 5 min, NaIO4 (7.6 g, 35.6 mmol) was added and stirring was 
continued for 8 h. The mixture was filtered through celite, and the filtrate was diluted with water 
and extracted with ethyl acetate. The extracts were washed with brine and dried (MgSO4).  
Concentration in vacuo afforded a residue that was purified by flash chromatography (3:2 
EtOAc:hexane) providing oxo-rotenol 3 (3.8 g, 81%):  m.p. 129-131 oC. 1H NMR δ 2.28 (s, 3 H, 
8'-CH3), 3.22 (dd, J = 10.84 Hz, J = 16.08 Hz, 1 H, 4'-Hα), 3.38 (dd, J = 4.63 Hz, J = 5.10 Hz, 1 
H, 12a-H), 3.42 (dd, J = 6.68 Hz, J = 16.08 Hz, 1 H, 4'-Hβ), 3.84 (s, 3 H, 2-OCH3), 3.85 (s, 3 H, 
3-OCH3), 4.22 (dd, J = 5.18 Hz, J = 9.84 Hz, 1 H, 6-Hα), 4.58 (dd, J = 9.84 Hz, J = 11.07 Hz, 1 
H, 6-Hβ), 4.82 (ddd, J = 5.10 Hz, J = 5.18 Hz, J = 11.07 Hz, 1 H, 6a-H), 4.92 (br s, 1 H, 12-H), 
5.08 (dd, J = 6.68 Hz, J = 10.84 Hz, 1 H, 5'-H), 6.46 (s, 1 H, 4-H), 6.52 (d, J = 8.20 Hz, 1 H, 10-
H), 6.70 (s, 1 H, 1-H), 7.09 (d, J = 8.20 Hz, 1 H, 11-H). Anal. calcd. for C22H22O7•0.5 H2O:  C, 
64.86; H, 5.41; found:  C, 65.16; H, 5.94. HRMS:  m/z 398.1363 (calcd. for C22H22O7, 
398.1365). LRMS:  m/z 398 (M), 380 (M-H2O, 32), 192 (base). 
2.3 7'-(Z)-Iodorotenol (4) 
 To a suspension of Ph3PCH2I2 (6.0 g, 11.3 mmol) in THF (20 mL) was added NaN(TMS)2 
(11.5 mL, 1.0 M solution in THF, 11.5 mmol). Upon dissolution, the flask was cooled to -78 oC 
and HMPA (3 mL) was added. Oxo-rotenol 3 (3.7 g, 9.3 mmol) in THF (10 mL) was added 
slowly, and the solution was allowed to warm to room temperature.  The solution was diluted 
with water and extracted with CH2Cl2.  The combined extracts were washed with aqueous 
NaHSO3, water, and then dried (MgSO4). Concentration in vacuo afforded a residue that was 
purified by flash chromatography on silica gel (1:9 EtOAc:CH2Cl2) providing  Z-iodorotenol 4 
(1.4 g, 30%) as a foam. A few milligrams of 4 were purified by HPLC (Whatman Partisil 10, 9.4 
mm x 25 cm, 25% EtOAc/Hexane, tR = 23 min) for analysis. 1H NMR δ 1.89 (d, J = 1.42 Hz, 3 
H, 8'-CH3), 2.83 (dd, J = 9.66 Hz, J = 15.98 Hz, 1 H, 4'-Hα), 3.40 (dd, J = 4.26 Hz, J = 4.98 Hz, 
1 H, 12a-H), 3.48 (dd, J = 8.46 Hz, J = 15.98 Hz, 1 H, 4'-Hβ), 3.85 (s, 3 H, 2-OCH3), 3.86 (s, 3 
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H, 3-OCH3), 4.24 (dd, J = 5.13 Hz, J = 9.76 Hz, 1 H, 6-Hα), 4.61 (dd, J = 9.76 Hz, J = 11.34 Hz, 
1 H, 6-Hβ), 4.84 (ddd, J = 4.98 Hz, J = 5.13 Hz, J = 11.34 Hz, 1 H, 6a-H), 4.93 (d, J = 4.26 Hz, 1 
H, 12-H), 5.67 (dd, J = 8.46 Hz, J = 9.66 Hz, 1 H, 5'-H), 6.05 (d, J = 1.42 Hz, 1 H, 7'-H), 6.46 (d, 
J = 8.15 Hz, 1 H, 10-H), 6.48 (s, 1 H, 4-H), 6.71 (s, 1 H, 1-H), 7.07 (d, J = 8.15 Hz, 1 H, 11-H). 
Anal. calcd. for C23H23IO6: C, 52.87; H, 4.41; found: C, 53.42; H, 4.86. HRMS:  m/z 522.0546 
(calcd. for C23H23IO6 522.0539). LRMS(FAB): m/z 522 (M
+, 26), 505 (m-OH, 30), 307 (6), 
192 (base). 
2.4 7'-(Z)-Iodorotenone (5) 
 To a solution of iodorotenol (100 mg, 0.192 mmol) in dry acetonitrile (5.0 mL) was added 
activated MnO2 (250 mg, 2.88 mmol) in one portion under argon atmosphere at room 
temperature. The mixture was vigorously stirred for 1 min and immediately filtered through a 
pad of celite. The filtrate was evaporated under reduced pressure. The residue was purified by 
flash chromatography on silica gel (1:3 EtOAc: Hexane) to give Z-iodorotenone 5 (57 mg, 58%) 
as a colorless solid and recovered iodorotenol 4 (22 mg, 22%). m.p. 201-203 oC. 1H NMR δ 1.87 
(s, 3 H, 8'-CH3), 2.81 (dd, J = 9.63 Hz, J = 16.01 Hz, 1 H, 4'-Hα), 3.50 (dd, J = 8.88 Hz, J = 
16.01 Hz, 1 H, 4'-Hβ), 3.76 (s, 3 H, 2-OCH3), 3.80 (s, 3 H, 3-OCH3), 3.84 (d, J = 4.26 Hz, 1 H, 
12a-H), 4.17 (d, J = 12.03 Hz, 1 H, 6-Hα), 4.60 (dd, J = 3.24 Hz, J = 12.03 Hz, 1 H, 6-Hβ), 4.93 
(m, 1 H, 6a-H), 5.68 (dd, J = 8.88 Hz, J = 9.63, 1 H, 5'-H), 6.07 (s, 1 H, 7'-H), 6.45 (s, 1 H, 4-H), 
6.50 (d, J = 8.56 Hz, 1 H, 10-H), 6.74 (s, 1 H, 1-H), 7.83 (d, J = 8.56 Hz, 1 H, 11-H). Anal. 
calcd. for C23H21IO6: C, 53.08; H, 4.04; found: C, 52.93; H, 4.39. HRMS:  m/z 520.0378 (calcd. 
for C23H21IO6, 520.0383).  LRMS(FAB):  m/z 520 (M
+, 47), 307 (26), 192 (46), 154 (base).   
 
2.5 7'-(Z)-Tributylstannylrotenol (6) 
 To a solution of iodorotenol 4 (1.44 g, 2.86 mmol) in toluene (22 mL) was added (Bu3Sn)2 
(3.2 g, 5.5 mmol) and Pd(PPh3)4 (0.042 g, 0.036 mmol).  The solution was refluxed under argon 
for 13 h and then allowed to cool to room temperature.  The reaction mixture was passed through 
a short silica gel column with hexane, CH2Cl2, and 1:9 EtOAc:CH2Cl2 as successive eluents.  
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Concentration of the appropriate fractions in vacuo afforded a residue that was further purified 
by HPLC (Whatman Partisil 10, 9.4 mm x 50 cm, 20% EtOAc/Hexane, 4 mL/min, ) to give 
tributylstannylrotenol 6 (200 mg, 10%) as a colorless oil. 1H NMR δ 0.85-0.93 (m, 15 H, 3 
CH3CH2), 1.26-1.36 (m, 6 H, 3 CH2), 1.44-1.50 (m, 6 H, 3 CH2), 1.89 (d, J = 1.22 Hz, 3 H, 8'-
CH3), 2.95 (dd, J = 9.34 Hz, J = 15.75 Hz, 1 H, 4'-Hα), 3.25 (dd, J = 9.34 Hz, J = 15.75 Hz, 1 H, 
4'-Hβ), 3.39 (dd, J = 4.29 Hz, J = 5.28 Hz, 1 H, 12a-H), 3.84 (s, 3 H, 2-OCH3), 3.85 (s, 3 H, 3-
OCH3), 4.24 (dd, J = 4.72 Hz, J = 9.78 Hz, 1 H, 6-Hα), 4.62 (dd, J = 9.78 Hz, J = 11.34 Hz, 1 H, 
6-Hβ), 4.83 (ddd, J = 4.72 Hz, J = 5.28 Hz, J = 11.34 Hz, 1 H, 6a-H), 4.92 (br s, 1 H, 12-H), 5.12 
(t, J = 9.34 Hz, 1 H, 5'-H), 5.73 (d, J = 1.22 Hz, 1 H, 7'-H), 6.43 (d, J = 8.10 Hz, 1 H, 10-H), 6.46 
(s, 1 H, 4-H), 6.70 (s, 1 H, 1-H), 7.04 (d, J = 8.10 Hz, 1 H, 11-H). Anal. calcd. for C35H50O6Sn:  
C, 61.40; H, 7.31; found:  C, 61.56; H, 7.42.  
 
2.6 7'-(Z)-Tributylstannylrotenone (7)  
 To a solution of tributylstannylrotenol 6 (75 mg, 0.11 mmol) in CH3CN (10 mL) was added 
MnO2 (250 mg, 2.8 mmol).  The mixture was stirred 10 min at room temperature and then 
filtered through celite.  Concentration of the filtrate in vacuo afforded a residue which was 
purified by HPLC (Whatman Partisil 10, 9.4 mm x 25 cm, 20% EtOAc/Hexane, tR = 15 min) to 
give the tributylstannylrotenone 7 (29 mg, 39%) as an oily foam. 1H NMR δ 0.84-0.91 (m, 15 H, 
3 CH3CH2), 1.22-1.34 (m, 6 H, 3 CH2), 1.42-1.52 (m, 6 H, 3 CH2), 1.87 (d, J = 1.27 Hz, 3 H, 8'-
CH3), 2.96 (dd, J = 9.33 Hz, J = 15.88 Hz, 1 H, 4'-Hα), 3.29 (dd, J = 9.33 Hz, J = 15.88 Hz, 1 H, 
4'-Hβ), 3.76 (s, 3 H, 2-OCH3), 3.81 (s, 3 H, 3-OCH3), 3.84 (d, J = 3.48 Hz, 1 H, 12a-H), 4.18 (d, 
J = 12.06 Hz, 1 H, 6-Hα), 4.62 (dd, J = 3.03 Hz, J = 12.06 Hz, 1 H, 6-Hβ), 4.93 (dd, J = 3.03 Hz, 
J = 3.48 Hz, 1 H, 6a-H), 5.16 (t, J = 9.33 Hz, 1 H, 5'-H), 5.77 (d, J = 1.27 Hz, 1 H, 7'-H), 6.46 (s, 
1 H, 4-H), 6.49 (d, J = 8.56 Hz, 1 H, 10-H), 6.78 (s, 1 H, 1-H), 7.84 (d, J = 8.56 Hz, 1 H, 11-H). 
Anal. calcd. for C35H48O6Sn•1/2 H2O:  C, 60.78; H, 6.95; found:  C, 60.50; H, 6.92; 
LRMS(FAB):  m/z 683 (M+, 19), 627 (M-C4H9, base), 513 (M-3xC4H9, 11), 192 (37), 179 (65). 
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2.7  7'-(Z)-[125I]Iodorotenol  (8) 
 To a solution of tributylstannylrotenol 6 (1 mg) in THF (200 μL) were successively added 
Na[125I]I (1.5 mCi), 0.61 M NaOAc (pH 4.5, 50 μL), and 2:1 30% H2O2:AcOH (25 μL).  The 
reaction mixture was stirred for 1 min at room temperature and then quenched with 50 μL 10% 
Na2S2O3(aq). The mixture was diluted with 350 μL of water and was injected onto a Whatman 
Partisil 10 ODS-3 HPLC column (9.4 mm x 50 cm, 60/40 MeOH/H2O, 4 mL/min). Product 
fractions were pooled and diluted with an equal volume of water and passed through a Waters 
C18 Sep-Pak® Classic cartridge. The trapped product was eluted from the Sep-Pak with 3 mL 
ethanol providing 1.3 mCi (81%) of Z-[125I]iodorotenol 8. Radiochemical purity of >95% was 
determined by HPLC on a Waters μ-Bondapack column (3.9 mm x 30 cm, 70/30 MeOH/ H2O - 
20 mM triethylammonium phosphate pH 7.4, 2 mL/min, tR = 3.4 min). The product was stored 
in ethanol at -80 oC in a sealed vial. 
 
2.8  7'-(Z)-[125I]Iodorotenone  (9) 
 To a solution of tributylstannylrotenone 7 (0.75 mg, 1.1 mmol) in THF (200 μL) were 
successively added Na[125I]I (5 mCi), 0.61 M NaOAc (pH 4.5, 50 μL), and 2:1 30% 
H2O2:AcOH (25 μL).  The reaction mixture was stirred for 1 min at room temperature and then 
quenched with 40 μL 10% Na2S2O3(aq).  The mixture was diluted with 350 μL of water and was 
injected onto a Whatman Partisil 10 ODS-3 HPLC column (9.4 mm x 50 cm, 60/40 MeOH/H2O, 
6 mL/min). Product fractions were pooled and diluted with an equal volume of water and passed 
through a Waters C18 Sep-Pak® cartridge. The trapped product was eluted from the Sep-Pak 
with 3 mL ethanol providing 2.4 mCi (48%) of Z-[125I]iodorotenone 9. Radiochemical purity of 
>95% was determined by HPLC on a Waters μ-Bondapack column (3.9 mm x 30 cm, 70/30 
MeOH/ H2O - triethylammonium phosphate pH 7.4, 2 mL/min, tR = 6.0 min). The product was 
stored in ethanol at -80 oC in a sealed vial. 
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2.5 In Vivo Biodistribution Studies 
 All animal experiments were carried out in compliance with the Guidelines for Care and Use 
of Research Animals established by the Lawrence Berkeley National Laboratory Animal Welfare 
and Research Committee. 
 The ethanol solution of either Z-[125I]iodorotenol 8 or Z-[125I]iodorotenone 9 was diluted with 
isotonic saline to a final concentration of 5% ethanol. Isoflurane anesthetized Sprague-Dawley 
male rats (~200 g) were injected in the tail vein with the 15-20 μCi of the either 8 or 9. At 1h, 2h 
and 24h post injection, rats (n=3-7 per time point) were euthanized by decapitation under general 
anesthesia.  Blood and organs were removed, weighed and assayed for radioactivity using a 
Packard Gamma Counter. The percent injected dose per gram of tissue was determined. 
 
3. Results  
3.1 Synthesis of Iodorotenol, Iodorotenone and the corresponding tributylstannyl precursors 
 The synthetic pathway for the preparation of iodorotenol 4 and iodorotenone 5 is shown in 
Scheme 1. Commercially available rotenone 1 was quantitatively converted to a single isomer of 
rotenol 2 by selective sodium borohydride reduction of the 12-carbonyl group.[26] Oxidative 
cleavage of the 6'-7' olefin with osmium tetroxide gave the 6' ketone intermediate 3 in 61% 
yield. The subsequent Wittig reaction with (iodomethyl)-triphenylphosphonium iodide ylide 
gave exclusively the 7'-(Z)-iodorotenol 4 in 25-30% yield. Based on NMR and HPLC 
examination a single isomer was predominantly formed (>99%). The Z stereoisomer 
configuration was independently confirmed by NOE NMR studies (unpublished results). The 
overall yield of iodorotenol from rotenone was 18%. 
Oxidation of the 12 hydroxy group of Z-iodorotenol 4 gave Z-iodorotenone 5 in one minute 
using activated manganese dioxide. Typical yields for this reaction ranged from 25-58% with 
recovery of a significant amount (~25%) of starting iodorotenol and a by-product. When the 
oxidation time was increased to five minutes the starting material was completely consumed, 
however, the Z-iodorotenone yield decreased significantly with a concomitant increase in the by-
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product.  The overall yield of Z-iodorotenone for the four-step conversion from rotenone was 5-
11%. 
The synthesis of the vinyl stannane labeling precursors from the common intermediate 
iodorotenol 4 is shown in Scheme 2. Reaction of Z-iodorotenol 4 with hexabutylditin using 
catalytic tetrakis(triphenylphosphine)-palladium (0) gave the 7'-(Z)-tributylstannylrotenol 6 in 
low yield (10-15%). Subsequent oxidation of 6 to the corresponding 7'-(Z)-
tributylstannylrotenone 7 was accomplished with manganese dioxide. The constraints of the 
oxidation reaction are the same as previously described for the conversion of 4 to 5 and account 
for the moderate oxidation yield of 40%. The overall yield of the stannylrotenol 6 and the 
stannylrotenone 7 from starting rotenone is 1.8% and 0.7%, respectively. 
 
3.2 Synthesis of radioiodinated iodorotenone and iodorotenol 
 The radioiodination reactions are shown in Scheme 2. The formation of both radioiodinated 
compounds occured rapidly by iododestannylation using sodium [125I]iodide in the presence of in 
situ derived peracetic acid. The isolated yield of Z-[125I]iodorotenol (75-80%) was typically 
greater than that of the [125I]iodorotenone (~50%). The Z-[125I]iodoroteno1 8 and Z-
[125I]iodorotenone 9 were very stable when stored in ethanol at –80˚C. The degradation of the 
stored material, verified by HPLC, was less than 3% per month. 
  
3.3 In Vivo Biodistribution Studies 
 The distribution of the radioiodinated rotenone analogs at 1h, 2h and 24h was evaluated in 
~200 gram male Sprague-Dawley rats. The tissue biodistribution of 7'-(Z)-[125I]iodorotenol 8 is 
presented in Table 1 and that of 7'-(Z)-[125I]iodorotenone 9 in Table 2. Both compounds were 
rapidly taken up in the heart (1.7 %ID/g for 8 and 3.7%ID/g for 9). The initial amount of tracer 
that remained in the blood was inversely proportional to the heart uptake with the Z-iodorotenol 
8 blood values nearly double that of the Z-iodorotenone 9. The 1h uptake in the rest of the 
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tissues was comparable for both compounds. Interestingly, there is considerable uptake of the 
tracer in the brain for both compounds during the first hour.  
 The distribution of Z-iodorotenol 8 does not significantly change in most tissues between 1 h 
and 2 h post injection, with the exception of the kidneys and brain (P < 0.02), yet by 24h there is 
significant washout (43-92%) from all tissues with the exception of the thyroid. Z-Iodorotenone 
9 shows significant moderate (7-26%; P < 0.03) washout by 2 h from all tissues except for blood, 
lung, muscle, thyroid and fat. By 24 h there is significant loss of tracer  (53-89%) from all tissues 
with the exception of thyroid and fat. 
 The rate of in vivo deiodination as evidenced by the percent injected dose in the thyroid is 
comparable for both compounds. The calculated linear thyroid accumulation rate appears to be 
about 0.15-0.2% per hour over the first 24 h. The rats were not pretreated with potassium 
chloride to block radioiodide uptake in the thyroid tissue. 
 Heart-to-tissue ratios were calculated for the blood, lung and liver. These values are given for 
Z-iodorotenol 8 and Z-iodorotenone 9 in Tables 1 and 2, respectively. The heart-to-blood ratio 
was the highest at the 1 h time point for each compound with the Z-iodorotenone ratio being 
four-fold higher than the Z-iodorotenol (28.9 compared to 6.6). The heart-to-blood ratios for 
both compounds decreased significantly (P < 0.03) at each time point up to the end of the study 
at 24 h post injection. The heart-to-lung ratio was again highest at 1 h post injection for both 
tracers (3.1 for 8 and 10.7 for 9). There was no significant change in the ratio for either tracer 
between 1 and 2 hours. By 24 h the heart-to-lung ratio for Z-iodorotenone dropped by nearly 
43% to 6.1 while there was no change in the ratio (3.1-3.2) for the Z-iodorotenol over the entire 
study period. The 1 h heart-to-liver ratio for Z-iodorotenol was just over 1. It remained 
unchanged at 2h but increased to 1.8 between 2h and 24h. Z-Iodorotenone heart-to-liver ratios 
remained around 2.4 throughout the course of the study. 
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4.0 Discussion 
 The two iodinated rotenoids were synthesized in good yield from commercially available 
rotenone in three to four steps. All of the reactions gave predominantly the desired products with 
the exception of the manganese dioxide mediated oxidation of the rotenols to rotenones. Based 
on our work with the fluororotenones and literature precedence [27, 28] the major by-product of 
the oxidation was identified as the 6a-12a unsaturated compound. The oxidation of the 
iodorotenone to the 6a-12a dehydro-iodorotenone competes with the conversion of iodorotenol 
to iodorotenone. Thus, optimizing the reaction time and amount of manganese dioxide is critical 
for suitable yields of the iodorotenone. 
 As with the manganese dioxide oxidations, unavoidable oxidation by the peracetic acid 
during the radiochemical reactions may be impacting the Z-[125I]iodorotenone yield. It does not 
appear that the Z-[125I]iodorotenol yield is affected by the peracetic acid as the yields are 
consistently high, 75-80%. On the other hand the Z-[125I]iodorotenone or the tributylstannyl-
rotenone precursor appear to be sensitive to peracetic acid oxidation as evidenced by the 
significantly lower product yield, ~50%, and increased by-product formation observed on the 
semi-preparative HPLC chromatogram. While a thorough investigation of oxidant concentrations 
or alternative oxidants was not undertaken for the iodorotenone reaction, increasing the reaction 
time prior to quenching decreased the iodorotenone to by-product ratio. It is known from our 
work with the rotenoids (unpublished data) that a variety of other oxidizing agents  did not 
improve the overall yield nor the desired rotenone-to-byproduct ratio.  
 An optimal cardiac flow tracer possesses the following characteristics, rapid and high 
extraction from the blood into the heart tissue, good retention in the cardiac tissue, linear uptake 
with flow at all flow rates, high heart-to-blood, high heart-to-lung and high heart-to-liver ratios 
as well as suitable clearance from liver and kidneys. There has been considerable effort to 
produce an ideal technetium-99m labeled tracer for SPECT perfusion imaging that surpass the 
less than ideal characteristics of the current clinical tracers, [99mTc]sestamibi and 
[99mTc]tetrofosmin. 
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 In the present study, Z-[125I]iodorotenol and Z-[125I]iodorotenone demonstrate good 
accumulation in the heart tissue at the 1 h time point. The uptake of Z-iodorotenone is 
comparable to the rodent heart uptake of [99mTc]sestamibi and [99mTc]tetrofosmin, 3.7 versus 3.2 
and 2.8 %ID/g respectively.[29] While the rate of accumulation, initial extraction and overall 
retention of the tracers is not captured in the present biodistribution study, Z-iodorotenone has 
been shown to have high first pass extraction (~84%) and better retention versus sestamibi 
(~48% first pass extraction) in isolated perfused rabbit heart studies.[21] The rodent 
biodistribution model does show tracer accumulation in the heart but is unable to discriminate 
the differences in extraction and retention that are important for selecting improved perfusion 
tracers. More sophisticated models of perfusion, such as the isolated perfused rabbit heart model, 
are necessary to examine the flow characteristics.  
 Both Z-iodorotenol and Z-iodorotenone are retained in the heart tissue from 1-2 h but ~85% 
of the activity washes out of the heart tissue from 2 to 24 h. Without a gold standard it is difficult 
to evaluate the relative retention of these tracers in the intact rodent model.  However, in the 
isolated perfused rabbit heart studies iodorotenone is retained in the heart to a greater extent than 
[99mTc]sestamibi.[21] The mechanism of accumulation and retention of the labeled rotenone 
analogs is based on the known inhibitory properties of rotenoids for NADH2 oxidase (Complex I 
of the electron transport chain) found on the inner membrane of mitochondria. This is strikingly 
similar to the known mechanism of cationic [99mTc]sestamibi and [99mTc]tetrofosmin 
accumulation and retention based on the potential gradient sustained in viable mitochondria.[30-
32] The high concentration of mitochondria in the heart tissue provides a reservoir for the flow 
tracers.  
 The avidity of these tracers for Complex I may also enable the evaluation of mitochondrial 
density in normal and diseased tissues. The degree of tracer uptake may correlate with the mass 
of mitochondria or with mitochondrial activity. This would include the original purpose for 
designing these tracers that was to measure the known loss of Complex I associated with 
neurodegenerative diseases. 
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 The uptake in the tissues surrounding the heart, most notably the lungs, define the contrast 
value of the tracer as a cardiac perfusion imaging agent. The crown of the liver also appears in 
the images near the heart so it is desirable to have a high heart-to-liver ratio in addition to a high 
heart-to lung ratio. The 1 h heart-to-lung and heart-to-liver ratios for Z-[125I]iodorotenol 8 and Z-
[125I]iodorotenone 9 are compared to the two clinical cationic SPECT tracers [99mTc]sestamibi 
and [99mTc]tetrofosmin in Figure 4. While the absolute heart uptake of iodorotenone was similar 
to sestamibi and tetrofosmin, Z-iodorotenone demonstrated significantly superior (P < 0.001) 
heart-to-lung ratios in the rodent at 1 h post injection. This contrast was sustained out to 2 h post 
injection. The heart-to-liver ratio for iodorotenone was equivalent to that of [99mTc]sestamibi (2.4 
vs. 2.6:1 ) yet 2.5-fold less than [99mTc]tetrofosmin (5.8:1). Taken together the distribution 
characteristics of Z-[125I]iodorotenone are favorable compared to the current clinical technetium-
99m tracers. 
 
5.0 Conclusion 
A new class of mitochondrial avid perfusion tracers have been identified. Z-[125I]Iodorotenone 
and Z-[125I]iodorotenol were produced in moderate to high yield and in a single step from their 
respective tributylstannyl precursors. The good heart uptake combined with the high heart-to-
blood and heart-to-lung ratios and good clearance from the kidneys demonstrates the favorable 
distribution characteristics of iodorotenone. Combined with the studies conducted in the isolated 
perfused rabbit heart, iodorotenone possesses desirable properties of an improved cardiac flow 
tracer that may prove valuable as a more sensitive identifier of significant coronary lesions.  
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 Table 1.  Biodistribution of 7’(Z)-[125I]iodorotenol (8) in Sprague-Dawley male rats 
Tissue 1 h (n=3) 2 h (n=4) 24 h (n=4) 
blood 0.259 ± 0.027 0.297 ± 0.031 0.080 ± 0.013 
heart 1.698 ± 0.074 1.586 ± 0.240 0.241 ± 0.042 
lung 0.548 ± 0.035 0.521 ± 0.050 0.078 ± 0.017 
liver 1.497 ± 0.104 1.376 ± 0.151 0.138 ± 0.018 
kidney 0.934 ± 0.009 0.822 ± 0.062 0.109 ± 0.009 
spleen 0.364 ± 0.024 0.335 ± 0.026 0.047 ± 0.005 
muscle 0.518 ± 0.093 0.491 ± 0.046 0.086 ± 0.012 
fat 1.066 ± 0.269 1.469 ± 0.385 0.213 ± 0.038 
brain 0.427 ± 0.030 0.297 ± 0.023 0.015 ± 0.002 
thyroida 0.139 ± 0.047 0.241 ± 0.072 5.037 ± 2.376 
heart:blood 6.600 ± 0.645 5.316 ± 0.363 3.016 ± 0.303 
heart:lung 3.107 ± 0.203 3.081 ± 0.629 3.199 ± 0.892 
heart:liver 1.136 ± 0.048 1.151 ± 0.109 1.755 ± 0.207 
 
Male Sprague-Dawley rats (~200 grams) were injected iv with 15-20 μCi of Z-
[125I]iodorotenol in 10% ethanol saline. 
Tissue distribution values are given as percent injected dose / gram and presented as 
mean ± standard deviation. 
a Thyroid values are given as percent injected dose/ organ. 
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Table 2.  Biodistribution of 7’ (Z)-[125I]iodorotenone (9) in Sprague-Dawley male rats 
Tissue 1 h (n=7) 2 h (n=6)  24 h  (n=4) 
blood 0.130 ± 0.020 0.135 ± 0.019 0.063 ± 0.010 
heart 3.707 ± 0.203 2.959 ± 0.244 0.607 ± 0.109 
lung 0.352 ± 0.055 0.326 ± 0.050 0.102 ± 0.017 
liver 1.557 ± 0.201 1.169 ± 0.188 0.267 ± 0.052 
kidney 1.257 ± 0.118 0.933 ± 0.092 0.212 ± 0.037 
spleen 0.275 ± 0.036 0.229 ± 0.013 0.062 ± 0.012 
muscle 0.507 ± 0.077 0.536 ± 0.074 0.199 ± 0.050 
fat 0.723 ± 0.193 1.018 ± 0.284 1.034 ± 0.144 
brain 0.436 ± 0.038 0.341 ± 0.035 0.040 ± 0.004 
thyroida 0.154 ± 0.057 0.339 ± 0.096 3.784 ± 0.647 
heart:blood       28.94 ± 3.61        22.35 ± 3.83 9.737 ± 2.239 
heart:lung       10.68 ± 1.34 9.316 ± 1.978 6.118 ± 1.716 
heart:liver 2.402 ± 0.209 2.570 ± 0.334 2.284 ± 0.310 
 
Male Sprague-Dawley rats (~200 grams) were injected iv with 15-20 μCi of Z-
[125I]iodorotenone in 10% ethanol saline. 
Tissue distribution values are given as percent injected dose / gram and presented as 
mean ± standard deviation. 
a Thyroid values are given as percent injected dose/ organ. 
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Figure and Scheme Legends: 
 
 
Figure 1: (5'R, 6aS, 12aS)-Rotenone structure shown with the conventional numbering system. 
[8] 
 
 
Figure 2: Heart-to-Liver and Heart-to-Lung uptake ratios for 8, 9, 99mTc-sestamibi and 99mTc-
tetrofosmin. Data for the technetium compounds were taken from reference [33]. Heart-to-Lung: 
Z-iodorotenone P < 0.001 vs. Z-iodorotenol; P < 0.001 vs 99mTc-sestamibi; and P < 0.001 vs 
99mTc-tetrofosmin. Heart-to-Liver: Z-iodorotenone P< 0.001 vs. Z-iodorotenol; P > 0.1 vs 99mTc-
sestamibi; and P < 0.001 vs 99mTc-tetrofosmin.  
 
 
Scheme 1: Preparation of unlabeled 7'(Z)-iodorotenol 4 and 7'(Z)-iodorotenone 5. 
 
 
Scheme 2: Synthesis of iodine-125 labeled 7'(Z)-iodorotenol 8 and 7'(Z)-iodorotenone 9 from the 
corresponding tributylstannane precursors.
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Scheme 2: 
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